Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions.
The US Patent and Trademark Office (USPTO) guidance on the patent eligibility of natural products in the US following the Myriad and Mayo court cases is fundamentally flawed, according to the life sciences IP experts invited to take part in the first LSIPR roundtable discussion held earlier this month in London.
“There are so many things wrong with it,” said Jane Wainwright, a partner at Potter Clarkson in Nottingham. “I, personally, don’t disagree with the ability to exclude natural products. If it is found in nature then I don’t think it should be patentable. But … they have overstepped the mark.”
As reported by LSIPR on September 4 [http://www.lifesciencesipreview.com/article/a-hostile-response-to-the-uspto-s-guidelines], the USPTO’s request for comment on the guidelines it issued following the decisions in the Association for Molecular Pathology v Myriad Genetics, Inc (Myriad) and Mayo Collaborative Services v Prometheus Laboratories, Inc (Mayo) court cases prompted an avalanche of replies, which were overwhelmingly negative.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
USPTO; biologicals; Myriad; patent eligibility; personalised medicine; US Supreme Court